

Oleg Timofeev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3886926/publications.pdf>

Version: 2024-02-01

18
papers

1,142
citations

687363

13
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

1820
citing authors

#	ARTICLE	IF	CITATIONS
1	Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16Ink4a-p19Arf pathway. <i>Nature Genetics</i> , 2004, 36, 343-350.	21.4	393
2	Cdc25 Phosphatases Are Required for Timely Assembly of CDK1-Cyclin B at the G2/M Transition. <i>Journal of Biological Chemistry</i> , 2010, 285, 16978-16990.	3.4	126
3	Wip1 Phosphatase Regulates p53-Dependent Apoptosis of Stem Cells and Tumorigenesis in the Mouse Intestine. <i>Cell Stem Cell</i> , 2007, 1, 180-190.	11.1	107
4	Increased subventricular zone-derived cortical neurogenesis after ischemic lesion. <i>Experimental Neurology</i> , 2010, 226, 90-99.	4.1	93
5	mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. <i>Nature Communications</i> , 2020, 11, 4684.	12.8	87
6	Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E8433-E8442.	7.1	73
7	p53 DNA Binding Cooperativity Is Essential for Apoptosis and Tumor Suppression In Vivo. <i>Cell Reports</i> , 2013, 3, 1512-1525.	6.4	66
8	A Subtle Change in p38 MAPK Activity is Sufficient to Suppress In Vivo Tumorigenesis. <i>Cell Cycle</i> , 2005, 4, 118-120.	2.6	45
9	p53 partial loss-of-function mutations sensitize to chemotherapy. <i>Oncogene</i> , 2022, 41, 1011-1023.	5.9	28
10	Human Cdc25A phosphatase has a non-redundant function in G2 phase by activating Cyclin A-dependent kinases. <i>FEBS Letters</i> , 2009, 583, 841-847.	2.8	25
11	Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses. <i>EMBO Journal</i> , 2019, 38, e102096.	7.8	22
12	Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases. <i>Nature Communications</i> , 2014, 5, 3981.	12.8	18
13	Phosphorylation Control of p53 DNA-Binding Cooperativity Balances Tumorigenesis and Aging. <i>Cancer Research</i> , 2020, 80, 5231-5244.	0.9	16
14	Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22288-22293.	7.1	14
15	Partial p53 reactivation is sufficient to induce cancer regression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 80.	8.6	11
16	Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo. <i>Cell Cycle</i> , 2020, 19, 109-123.	2.6	8
17	Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy. <i>Cancers</i> , 2021, 13, 2422.	3.7	6
18	p53 gain-of-function mutations promote metastasis via ENTPD5 upregulation and enhanced N-glycoprotein folding. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1288678.	0.7	4